These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

404 related items for PubMed ID: 12408503

  • 1. Role of mesalazine in acute and long-term treatment of ulcerative colitis and its complications.
    Schroeder KW.
    Scand J Gastroenterol Suppl; 2002; (236):42-7. PubMed ID: 12408503
    [Abstract] [Full Text] [Related]

  • 2. Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis.
    Feagan BG, Macdonald JK.
    Cochrane Database Syst Rev; 2012 Oct 17; 10():CD000543. PubMed ID: 23076889
    [Abstract] [Full Text] [Related]

  • 3. Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis.
    Wang Y, Parker CE, Bhanji T, Feagan BG, MacDonald JK.
    Cochrane Database Syst Rev; 2016 Apr 21; 4(4):CD000543. PubMed ID: 27101467
    [Abstract] [Full Text] [Related]

  • 4. Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis.
    Feagan BG, Macdonald JK.
    Cochrane Database Syst Rev; 2012 Oct 17; 10():CD000544. PubMed ID: 23076890
    [Abstract] [Full Text] [Related]

  • 5. Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis.
    Wang Y, Parker CE, Feagan BG, MacDonald JK.
    Cochrane Database Syst Rev; 2016 May 09; 2016(5):CD000544. PubMed ID: 27158764
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Systematic review: short-term adverse effects of 5-aminosalicylic acid agents in the treatment of ulcerative colitis.
    Loftus EV, Kane SV, Bjorkman D.
    Aliment Pharmacol Ther; 2004 Jan 15; 19(2):179-89. PubMed ID: 14723609
    [Abstract] [Full Text] [Related]

  • 8. Comparative efficacy and tolerability of pharmacological agents for management of mild to moderate ulcerative colitis: a systematic review and network meta-analyses.
    Nguyen NH, Fumery M, Dulai PS, Prokop LJ, Sandborn WJ, Murad MH, Singh S.
    Lancet Gastroenterol Hepatol; 2018 Nov 15; 3(11):742-753. PubMed ID: 30122356
    [Abstract] [Full Text] [Related]

  • 9. Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis.
    Murray A, Nguyen TM, Parker CE, Feagan BG, MacDonald JK.
    Cochrane Database Syst Rev; 2020 Aug 28; 8(8):CD000544. PubMed ID: 32856298
    [Abstract] [Full Text] [Related]

  • 10. Treatment of ulcerative colitis with oral mesalamine: advances in drug formulation, efficacy expectations and dose response, compliance, and chemoprevention.
    Sandborn WJ.
    Rev Gastroenterol Disord; 2006 Aug 28; 6(2):97-105. PubMed ID: 16699478
    [Abstract] [Full Text] [Related]

  • 11. Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis.
    Murray A, Nguyen TM, Parker CE, Feagan BG, MacDonald JK.
    Cochrane Database Syst Rev; 2020 Aug 12; 8(8):CD000543. PubMed ID: 32786164
    [Abstract] [Full Text] [Related]

  • 12. Balsalazide.
    Prakash A, Spencer CM.
    Drugs; 1998 Jul 12; 56(1):83-9; discussion 90. PubMed ID: 9664201
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Review article: high-dose aminosalicylates to induce and maintain remissions in ulcerative colitis.
    Hanauer SB.
    Aliment Pharmacol Ther; 2006 Oct 12; 24 Suppl 3():37-40. PubMed ID: 16961743
    [Abstract] [Full Text] [Related]

  • 15. Low dose balsalazide (1.5 g twice daily) and mesalazine (0.5 g three times daily) maintained remission of ulcerative colitis but high dose balsalazide (3.0 g twice daily) was superior in preventing relapses.
    Kruis W, Schreiber S, Theuer D, Brandes JW, Schütz E, Howaldt S, Krakamp B, Hämling J, Mönnikes H, Koop I, Stolte M, Pallant D, Ewald U.
    Gut; 2001 Dec 12; 49(6):783-9. PubMed ID: 11709512
    [Abstract] [Full Text] [Related]

  • 16. A practical guide to the management of distal ulcerative colitis.
    Ardizzone S, Bianchi Porro G.
    Drugs; 1998 Apr 12; 55(4):519-42. PubMed ID: 9561342
    [Abstract] [Full Text] [Related]

  • 17. The systemic load and efficient delivery of active 5-aminosalicylic acid in patients with ulcerative colitis on treatment with olsalazine or mesalazine.
    Støa-Birketvedt G, Florholmen J.
    Aliment Pharmacol Ther; 1999 Mar 12; 13(3):357-61. PubMed ID: 10102969
    [Abstract] [Full Text] [Related]

  • 18. Oral delayed-release mesalazine: a review of its use in ulcerative colitis and Crohn's disease.
    Prakash A, Markham A.
    Drugs; 1999 Mar 12; 57(3):383-408. PubMed ID: 10193690
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Adverse effects of sulfasalazine and treatment of ulcerative colitis with mesalazine.
    Nakajima H, Munakata A, Yoshida Y.
    J Gastroenterol; 1995 Nov 12; 30 Suppl 8():115-7. PubMed ID: 8563870
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 21.